Crossmark

Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada

Crossref DOI link: https://doi.org/10.1007/s41669-019-0131-6

Published Online: 2019-03-29

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Johansen, Pierre https://orcid.org/0000-0002-6287-7508
Håkan-Bloch, Jonas

Liu, Aiden R.

Bech, Peter G.

Persson, Sofie

Leiter, Lawrence A.
Funding

Funding for this research was provided by:

Novo Nordisk
License Information

Text and Data Mining valid from 2019-03-29
More Information

Article History

First Online: 29 March 2019

Compliance with Ethical Standards

:

: This study was supported and open access publication was sponsored by Novo Nordisk A/S.

: Pierre Johansen, Aiden R. Liu and Peter Bech are employees of Novo Nordisk. Pierre Johansen was employed by the Swedish IHE prior to the time of this study. Jonas Håkan-Bloch was employed by Novo Nordisk at the time this study was conducted. Sofie Persson is employed by IHE, which received grant funding from Novo Nordisk. Lawrence A. Leiter received no payment or services related to this study, but has received research support from AstraZeneca, Boehringer Ingelheim, Eli Lilly, GSK, Janssen, Merck, Novo Nordisk and Sanofi, and has been on advisory panels and provided continuing medical education for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi and Servier.